MABS-AUSTIN
| 中国学者近期发表的论文 | |
|---|---|
| 1. | Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. Author: Tan Q, Guo Q, Fang C, Wang C, Li B, Wang H, Li J, Guo Y. Journal: MAbs. 2012 Oct 2;4(6). [Epub ahead of print] |
| 2. | Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma. Author: Li S, Zhang D, Sun J, Li Z, Deng L, Zou B, Zhan J, Jiang W. Journal: MAbs. 2012 Mar 1;4(2). [Epub ahead of print] |
| 3. | Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. Author: Zhou B, Lin B, Li J, Qian W, Hou S, Zhang D, Kou G, Li B, Wang H, Chen Y, Guo Y. Journal: MAbs. 2012 Jan-Feb;4(1):110-9. doi: 10.4161/mabs.4.1.18349. |
| 4. | In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. Author: Chen L, Wang L, Shion H, Yu C, Yu YQ, Zhu L, Li M, Chen W, Gao K. Journal: MAbs. 2016 Jul 5:0. [Epub ahead of print] |
| 5. | Acid-induced aggregation propensity of nivolumab is dependent on the Fc. Author: Liu B, Guo H, Xu J, Qin T, Xu L, Zhang J, Guo Q, Zhang D, Qian W, Li B, Dai J, Hou S, Guo Y, Wang H. Journal: MAbs. 2016 Aug-Sep;8(6):1107-1117. Epub 2016 Jun 16. |
| 6. | Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir. Author: Ren H, Wang G, Wang S, Chen H, Chen Z, Hu H, Cheng G, Zhou P. Journal: MAbs. 2016 Aug-Sep;8(6):1156-1166. Epub 2016 May 11. |
| 7. | Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells. Author: Li Y, Fu T, Liu T, Guo H, Guo Q, Xu J, Zhang D, Qian W, Dai J, Li B, Guo Y, Hou S, Wang H. Journal: MAbs. 2016 Jul;8(5):951-60. doi: 10.1080/19420862.2016.1172150. Epub 2016 Apr 6. |
| 8. | XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. Author: Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, Weinzierl T, Rieder N, Bacac M, Ries CH, Kettenberger H, Schlothauer T, Friess T, Umana P, Klein C. Journal: MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16. |
| 9. | Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. Author: Chen W, Bardhi A, Feng Y, Wang Y, Qi Q, Li W, Zhu Z, Dyba MA, Ying T, Jiang S, Goldstein H, Dimitrov DS. Journal: MAbs. 2016 May-Jun;8(4):761-74. doi: 10.1080/19420862.2016.1160180. Epub 2016 Mar 10. |
| 10. | A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. Author: Shi X, Deng Y, Wang H, Ji G, Tan W, Jiang T, Li X, Zhao H, Xia T, Meng Y, Wang C, Yu X, Yang Y, Li B, Qin ED, Dai J, Qin CF, Guo Y. Journal: MAbs. 2016 Apr;8(3):574-84. doi: 10.1080/19420862.2016.1148850. Epub 2016 Feb 23. |